KEY TAKEAWAYS
- The study aimed to investigate the predictive value of NLR and PLR in cervical cancer outcomes following chemoradiotherapy.
- Researchers concluded that NLR and PLR levels in pre-treatment peripheral blood predict DFS in pts with stage IB2-IIB cervical cancer.
Cervical cancer ranks as the 2nd most fatal tumour globally among females. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been widely applied to the diagnosis of cancers.
Jing Yu and the team aimed to assess the predictive potential of NLR and PLR in determining DFS outcomes following treatment.
They performed an inclusive analysis of clinicopathologic data from 180 patients (pts) diagnosed with stage IB2-IIB cervical cancer who underwent radical concurrent chemoradiotherapy between January 2018 and December 2019.
Receiver operating characteristic (ROC) curves were utilized to determine optimal cut-off values for NLR and PLR in predicting therapeutic outcomes. Associations between PLR and other clinicopathological factors with 1-year survival rates were explored through univariate and multivariate Cox regression analyses.
Researchers found that NLR was significantly associated with the therapeutic effects of neoadjuvant therapy, with an optimal cut-off value of 2.89. The area under the ROC curve (AUC) was 0.848 (95% CI: 0.712-0.896), sensitivity was 0.892 (95% CI: 0.856-0.923), and specificity was 0.564 (95% CI: 0.512-0.592). Similarly, PLR showed a significant association with therapeutic effects, with an optimal cut-off value of 134.27.
The AUC was 0.766 (95% CI: 0.724-0.861), sensitivity was 0.874 (95% CI: 0.843-0.905), and specificity was 0.534 (95% CI: 0.512-0.556). Lymphatic metastasis (95% CI: 1.435-5.461), [95% CI: 1.336-4.281], depth of invasion ([95% CI: 1.281-3.546], [95% CI: 1.183-3.359]) and tumour size ([95% CI: 1.129-3.451], [95% CI: 1.129-3.451]) were independent factors influencing overall survival (OS) and disease-free survival (DFS) in pts with cervical cancer. Additionally, NLR (95% CI: 1.256-4.039) and PLR (95% CI: 1.281-3.546) were identified as independent factors affecting DFS.
The study concluded that NLR and PLR levels in pre-treatment peripheral blood can predict DFS in pts with stage IB2-IIB cervical cancer.
The study received no funds.
Source: https://pubmed.ncbi.nlm.nih.gov/38864403/
Yu J, Huang L, Dong T, et al. (2024). “Prediction of outcomes after chemoradiotherapy for cervical cancer by neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio.” J Obstet Gynaecol. 2024 Dec;44(1):2361858. doi: 10.1080/01443615.2024.2361858. Epub 2024 Jun 12. PMID: 38864403.
